On Oct. 29 the company announced it was withdrawing ESP V and asked the PUCO to let it operate under its former ESP IV plan until it can devise a new ESP that regulators approve. The company intends ...

Coronary artery spasm. Monitor for myocardial ischemia during and after administration (esp. IV use; do not exceed recommended infusion rate). Phenylketonuria (ODT form). Hepatic dysfunction.